Company news

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Two St. Vincent Health hospitals—Saint John’s Health System and St. Vincent Jennings Hospital—have started using the DOCS4DOCS service provided by the Indiana Health Information Exchange.  DOCS4DOCS centralizes in electronic format all the lab results, radiology reports, transcriptions, pathology and hospital admissions reports, discharge and transfer reports from all participating Indiana hospitals, physician practices, labs and radiology centers. The service, which swaps more than 6 million messages each month, is paid for by hospitals and laboratories but provided free of charge to physicians. The exchange, based in Indianapolis, now has more than 80 hospitals and 19,000 physicians participating in its medical-record-sharing services.

Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by former Eli Lilly and Co. executives, has been acquired by Swiss life sciences giant Roche. Some details of the transaction will be disclosed in February. Roche’s holdings include Roche Diagnostics, which employs more than 3,000 in Indianapolis at its North American headquarters. Marcadia has about a dozen employees at its 11711 N. Meridian St. headquarters, who have so far been sustained by the millions of dollars Marcadia has raised in venture capital and its partnerships with large drug companies.. Marcadia has been focusing on drugs to treat metabolic diseases such as diabetes and obesity. It previously partnered with drug giant New Jersey-based Merck & Co. Inc. and with Indianapolis-based Lilly. Last June, Marcadia and Lilly struck a deal to develop short-acting glucagon drugs to treat severe hypoglycemia. Roche’s big hope for a new diabetes drug, taspoglutide, had its clinical trials suspended in September due to severe digestive-tract side effects.
 

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In